Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.34 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.34 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.34 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HK1 | P19367 | 1/20 | 0.32 |
| ▸ | HK2 | P52789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16708473 | 0.86 | TMPRSS2 (0.49) | TMPRSS2LGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL25912551 | 0.85 | TMPRSS2 (0.35) | TMPRSS2LGALS8 | |
| SCHEMBL16708472 | 0.83 | TMPRSS2 (0.42) | TMPRSS2TDP1ADORA1HTT | |
| SCHEMBL16708477 | 0.82 | TMPRSS2 (0.47) | TMPRSS2POLBLGALS9LGALS1LGALS3 | |
| SCHEMBL19101768 | 0.81 | TMPRSS2 (0.42) | TMPRSS2POLBLGALS9LGALS1LGALS3 | |
| SCHEMBL16708480 | 0.79 | TMPRSS2 (0.43) | TMPRSS2POLBTDP1ADORA1 | |
| SCHEMBL16708492 | 0.79 | TMPRSS2 (0.41) | TMPRSS2TDP1HTT | |
| SCHEMBL24917286 | 0.78 | TMPRSS2 (0.46) | TMPRSS2POLBTDP1 | |
| SCHEMBL24791240 | 0.78 | TMPRSS2 (0.61) | TMPRSS2POLBTDP1HTT | |
| SCHEMBL16708478 | 0.78 | TMPRSS2 (0.39) | TMPRSS2POLBTDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885LGALS8 1481/4885POLB 95/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885LGALS8 1481/4885POLB 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.